Prospective, randomized, double-blind, placebo-controlled evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
Paidas MJ, Tita ATN, Macones GA, Saade GA, Ehrenkranz RA, Triche EW, Streisand JB, Lam GK, Magann EF, Lewis DF, Dombrowski MP, Werner EF, Branch DW, Habli MA, Grotegut CA, Silver RM, Longo SA, Amon E, Cleary K, How HY, Novotny SR, Grobman WA, Whiteman VE, Wing DA, Scifres CM, Sibai BM. Prospective, randomized, double-blind, placebo-controlled evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia. American Journal Of Obstetrics And Gynecology 2020, 223: 739.e1-739.e13. PMID: 32780999, DOI: 10.1016/j.ajog.2020.08.004.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAdolescentAdultAntithrombin ProteinsCesarean SectionDelivery, ObstetricDouble-Blind MethodFemaleFetal DistressGestational AgeHumansInfant, Premature, DiseasesInfant, Small for Gestational AgeMiddle AgedNeonatal SepsisPerinatal MortalityPre-EclampsiaPregnancyPregnancy Trimester, SecondPregnancy Trimester, ThirdProspective StudiesRecombinant ProteinsYoung AdultConceptsRecombinant human antithrombinPreterm preeclampsiaExpectant managementMorbidity scoreHuman antithrombinPlacebo-controlled clinical trialPlacebo-controlled evaluationPlacebo-controlled trialMedian gestational ageMaternal complicationsVersus PlaceboFetal outcomesMaternal outcomesPreterm deliveryEndothelial dysfunctionSecondary outcomesSingleton pregnanciesStandard therapyLoading dosePrimary outcomeWeeks' gestationGestational ageContinuous infusionClinical trialsSaline infusion